David Moadel

David Moadel

Expertise: Stocks, Options, Precious metals, Bitcoin, Altcoins

Education: Master's degree in education from the American College of Education, Bachelor's degree in education from Florida Atlantic University, Associate's degree in liberal arts from Palm Beach Community College

About David:
David Moadel is a financial writer for InvestorPlace.com. He has a master’s degree in education and has authored financial content for multiple websites.

David is also active as a social media influencer, with tens of thousands of followers on YouTube, Twitter, StockTwits, and other popular sites. David writes on topics ranging from stocks to cryptocurrencies, options, precious metals, bonds, futures, and other areas of finance.

Focusing on data rather than emotions, David is always on the lookout for new pathways to financial freedom. Count on David for wealth-building strategies and resources for investors and traders of all financial backgrounds.

You can follow David on YouTube, Twitter, StockTwits and LinkedIn.

Recent Articles

CMG Stock Pops as Chipotle Beats on Earnings, Raises Prices

Higher food prices aren't a pleasure for Chipotle's customers, but they're willing to pay up and a profit beat is sending CMG stock higher.

PayPal (PYPL) Stock Gains as Activist Investor Elliott Takes Stake

Sometimes, one investor's influence can be highly impactful. Such may be the case with PayPal, and PYPL stock is moving higher on fresh news.

GE Stock Jumps 6% as General Electric Reports Positive Earnings

Inflation and supply chain issues could cause problems for General Electric, but GE stock is still moving higher on strong quarterly results.

Why Is Ayala Pharmaceuticals (AYLA) Stock Up 100%+ Today?

Despite a lack of new clinical news concerning Ayala Pharmaceuticals, the short-squeeze mob seems to have taken control of AYLA stock.

JNJ Stock Alert: What to Know as Johnson & Johnson Releases Clinical Trial Data

JNJ stock managed to stay above water during a red-market day due to encouraging clinical trial data for a hard-to-treat condition.